Background And Objective: Neuro-ophthalmic manifestations of cancer are vast and early recognition of a serious ocular condition due to either cancer or its therapy is important for both vision preservation as well as providing valuable treatment and prognostic information regarding the underlying malignancy. This review focuses on direct and indirect effects of cancer on the eye and its adnexa, hematologic malignancy, complications of traditional and novel oncologic therapies, and paraneoplastic syndromes as they relate to the eye as these disorders can lead to potentially devastating or irreversible vision loss.
Methods: PubMed was searched primarily for the following topics: optic nerve infiltration, primary vitreoretinal lymphoma (PVRL), ocular paraneoplastic disorders, and ophthalmic complications of cancer therapeutics. Literature was selected based on historical significance and landmark studies (e.g., Cross et al. series of paraneoplastic optic neuritis patients; Chan's textbook on primary intraocular lymphoma) as well as publications published after 2000. References from select studies were additionally included. Given the sparsity of literature on many subjects, most publications were included during this time frame in our review.
Key Content And Findings: There are several ophthalmic entities that the oncologist should be aware of including leukemic optic nerve infiltration, PVRL, paraneoplastic syndromes as they related to the eye, and adverse effects of therapeutics. Unfortunately, given the rarity of some of these entities [e.g., paraneoplastic optic neuropathy (PON), cancer-associated retinopathy (CAR)], diagnosis can be difficult and treatment options are often limited.
Conclusions: Oncologists can develop a set of basic ophthalmology examination skills that will help to triage and manage patient eye complaints. In certain instances, oncologists have the potential to avert devastating vision loss with early recognition of neuro-ophthalmic complications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21037/cco-21-137 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids Presenting With Predominantly Neuro-Ophthalmic Features.
J Neuroophthalmol
January 2025
Departments of Ophthalmology and Visual Sciences (HMM, AH, EM), and Radiology (DMM), University of Toronto, Toronto, Canada; Department of Ophthalmology (LD), McMaster University, Hamilton, Canada; Departments of Ophthalmology and Visual Sciences, and Neurology (JDT), University of Michigan, Ann Arbor, Michigan; Department of Neurology (JDT), University of Michigan, Ann Arbor, Michigan; Division of Neurology, Department of Medicine (EM), University of Toronto, Toronto, Canada.
Background: Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) is a rare and poorly understood inflammatory disorder of the central nervous system centered on the pons. It has a characteristic imaging appearance with enhancing and T2-hyperintense punctate and curvilinear lesions in the pons. The lesions lack restricted diffusion and have relatively little perilesional edema.
View Article and Find Full Text PDF[Research progress on the manifestations prevention and treatment of immune-related adverse events in the neuro-ophthalmic efferent system related to immune checkpoint inhibitors].
Zhonghua Yan Ke Za Zhi
January 2025
Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology ＆ Visual Sciences, Beijing100730, China.
Immune checkpoint inhibitors (ICI), as a new type of targeted therapeutic drugs, have demonstrated durable efficacy in cancer treatment. However, some patients receiving ICI treatment may be affected by immune-related adverse events (irAE). Compared with irAE in skin tissues, gastrointestinal system, etc.
View Article and Find Full Text PDFOcular Immune-Related Adverse Events Associated with PD-1 Inhibitors: From Molecular Mechanisms to Clinical Management.
Semin Ophthalmol
November 2024
Department of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
Article Synopsis
- This text emphasizes the need for ophthalmologists and oncologists to better understand ocular immune-related adverse events (irAEs) caused by PD-1 inhibitors for early detection and management.
- A review of 70 case reports found that melanoma and lung cancer were the most common malignancies associated with these adverse events, primarily involving the PD-1 inhibitors pembrolizumab and nivolumab.
- The most frequent ocular complications included uveitis and myasthenia gravis, typically managed with steroids, while severe cases may necessitate stopping the PD-1 inhibitors, highlighting the importance of collaboration between specialties for effective patient care.
Emerging Ocular Side Effects of Immune Checkpoint Inhibitors: A Comprehensive Review.
Biomedicines
November 2024
Department of Surgery, Division of Ophthalmology, University of Sherbrooke, Sherbrooke, QC J1G 2E8, Canada.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, offering significant improvements in patient survival across various malignancies. However, their use is associated with a broad spectrum of immune-related adverse events (irAEs), including those affecting the eye and its surrounding structures, collectively termed ocular irAEs (OirAEs). Although rare, OirAEs (e.
View Article and Find Full Text PDFOverview of Neuro-Ophthalmic Findings in Leukodystrophies.
J Clin Med
August 2024
Children's Hospital, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
Leukodystrophies are a group of rare genetic diseases that primarily affect the white matter of the central nervous system. The broad spectrum of metabolic and pathological causes leads to manifestations at any age, most often in childhood and adolescence, and a variety of symptoms. Leukodystrophies are usually progressive, resulting in severe disabilities and premature death.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!